Yuri A. Piven¹, Danila V. Sorokin², Nastassia A. Varabyeva¹, Alexandra L. Mikhaylova², Fedor B. Bogdanov², Elena V. Shafranovskaya¹, Raman M. Puzanau³, Fedor A. Lakhvich¹, Alexander M. Scherbakov^2,4,*

Oncology Research, Vol.33, No.12, pp. 4049-4072, 2025, DOI:10.32604/or.2025.067832 - 27 November 2025

Abstract Background: The most aggressive forms of breast cancer are characterized by independence from steroid hormones but a strong dependence on growth factors. In such cancer cells, oncogenic receptors, including human epidermal growth factor receptor 2 (HER2), are activated, and their targeted inhibition represents an attractive therapeutic strategy. The study aimed to develop small-molecule potential dual heat shock protein 90 (HSP90)-HER2 inhibitors and evaluate them as anticancer agents in HER2-positive cells. Methods: The research project involved obtaining a series of compounds with potential dual inhibitory activity against HSP90 and HER2 by targeted organic synthesis, which was… More > Graphic Abstract

Yi Feng^1,#, Haoxin Yang², Guicai Liang¹, Jun Chen³, Tao Li¹, Yingjuan Wang⁴, Jilin Chang¹, Yan Li³, Meng Yang¹, Xilong Zhou¹, Zhiqiang Wang^5,*, Chunlei Ge^1,*

Oncology Research, Vol.33, No.12, pp. 3801-3836, 2025, DOI:10.32604/or.2025.067824 - 27 November 2025

Abstract Immune checkpoint inhibitor (ICI) has limited efficacy in the treatment of immune “cold” tumors. Due to insufficient T cell infiltration and heterogeneous programmed death ligand 1 (PD-L1) expression, the ORR is only 5%–8% compared with 30%–40% of “hot” tumors. This article reviews the synergistic mechanism, clinical efficacy and optimization strategy of oncolytic virus (OVs) combined with ICIs in the treatment of refractory malignant tumors. Systematic analysis of mechanistic interactions across tumor types and clinical trial data demonstrates that OVs transform the immunosuppressive microenvironment by inducing immunogenic cell death and activating innate immunity. Concurrently, ICIs enhance… More >

Heba A. S. El-Nashar^1,*, Ahmed T. Negmeldin^2,3,*, Aziza El Baz⁴, Marizé Cuyler⁵, Brandon Alston⁵, Namrita Lall^5,6,7, Naglaa S. Ashmawy^1,8,*

Phyton-International Journal of Experimental Botany, Vol.94, No.10, pp. 3269-3281, 2025, DOI:10.32604/phyton.2025.067998 - 29 October 2025

Abstract Pimenta dioica is a tropical Caribbean tree belonging to the family Myrtaceae, widely used in various human activities, including perfume production, food flavoring, natural pesticides, and medicine. This study aimed to explore the chemical composition of Pimenta dioica flower essential oil obtained via hydrodistillation using GC-MS analysis. Additionally, the oil’s tyrosinase inhibitory activity was investigated. The effectiveness of the oil’s major constituents in binding to tyrosinase was also evaluated through molecular docking simulations. GC-MS analysis identified fifteen compounds, with eugenol (70.59%) as the major component, followed by β-myrcene (10.54%), limonene (8.55%), β-ocimene (4.92%), α-phellandrene (1.39%), and linalool… More >

Chiao-Ping Chen^1,2, Yan-Jei Tang^1,2, You-Yan Cai¹, Yi-Ru Pan³, Chun-Nan Yeh^3,4, Wen-Kuan Huang^1,2, Chih-Hong Lo^1,2, Yu-Tien Hsiao^1,2, Hsuan-Jen Shih^1,*, Chiao-En Wu^1,2,4,5,*

Oncology Research, Vol.33, No.11, pp. 3429-3446, 2025, DOI:10.32604/or.2025.066672 - 22 October 2025

Abstract Background: KIT proto-oncogene, receptor tyrosine kinase (KIT, CD117) and platelet-derived growth factor-alpha (PDGFRA) are key drivers of gastrointestinal stromal tumors (GIST), but resistance to targeted therapy often arises from tumor protein p53 (p53) alterations and loss of cell cycle control. However, the role of p53 status in GIST therapeutic potential has rarely been studied, so this study aimed to employ both wild-type and mutant p53 GIST models to investigate how p53 dysfunction influences the efficacy of p53 pathway-targeted therapies. Methods: The efficacy of the mouse double minute 2 homolog (MDM2) inhibitor (HDM201) and the Wee1… More >

Takeshi Toyozumi^1,*, Hideaki Shimada², Hisahiro Matsubara¹

Oncology Research, Vol.33, No.11, pp. 3185-3206, 2025, DOI:10.32604/or.2025.065818 - 22 October 2025

Abstract Cancer immunotherapy has long been established as an important treatment option for cancers. In particular, Immune Checkpoint Inhibitor (ICI) has been reported to be effective against various gastrointestinal cancers (esophageal cancer, gastric cancer, colorectal cancer); however, the treatment phase in which ICI should be used and how it should be incorporated into the treatment strategy vary depending on the cancer type being treated. Multiple clinical trials and basic research on ICIs are currently underway, and new insights from these results will continue to change the clinical treatment strategy of gastrointestinal cancers. While it is desirable… More >

Xinyao Huang^1,#, Renjun Gu^2,3,#, Ziyun Li^4,*, Fangyu Wang^3,*

Oncology Research, Vol.33, No.10, pp. 2857-2902, 2025, DOI:10.32604/or.2025.066805 - 26 September 2025

Abstract Cold tumors, defined by insufficient immune cell infiltration and a highly immunosuppressive tumor microenvironment (TME), exhibit limited responsiveness to conventional immunotherapies. This review systematically summarizes the mechanisms of immune evasion and the therapeutic strategies for cold tumors as revealed by multi-omics technologies. By integrating genomic, transcriptomic, proteomic, metabolomic, and spatial multi-omics data, the review elucidates key immune evasion mechanisms, including activation of the WNT/β-catenin pathway, transforming growth factor-β (TGF-β)–mediated immunosuppression, metabolic reprogramming (e.g., lactate accumulation), and aberrant expression of immune checkpoint molecules. Furthermore, this review proposes multi-dimensional therapeutic strategies, such as targeting immunosuppressive pathways (e.g.,… More > Graphic Abstract

Yun Wang^1,2,#, Xin-Yu Li^1,3,#, Sheng-Li Wu^1,3, Pianchou Gongpan¹, Da-Hong Li², Chang-An Geng^1,3,*

Phyton-International Journal of Experimental Botany, Vol.94, No.8, pp. 2563-2574, 2025, DOI:10.32604/phyton.2025.068185 - 29 August 2025

Abstract Twelve lignans (1–12) isolated from Amomum tsao-ko leaves were evaluated for the inhibitory effects against α-glucosidase and PTP1B. Compounds 1−4 and 10 showed inhibition on α-glucosidase with inhibitory ratios ranging from 53.8% to 90.0%, while compound 10 demonstrated 56.1% inhibition on PTP1B at 200 μM. Notably, erythro-5-methoxy-dadahol A (2) and threo-5-methoxy-dadahol A (3) displayed obvious inhibition on α-glucosidase with IC₅₀ values of 33.3 μM and 22.1 μM, significantly outperforming acarbose (IC₅₀ = 344.0 μM). Kinetic study revealed that compound 3 maintained a mixed-type mode, engaging with both free enzyme and enzyme-substrate complex via non-competitive and uncompetitive mechanisms. Molecular docking simulations further clarified its More >

Jiao Li^1,2, Nurhayu Ab Rahman^1,3, Suharni Mohamad¹, Guang Yang⁴, Caixia Zhao^2,*

Oncology Research, Vol.33, No.9, pp. 2263-2278, 2025, DOI:10.32604/or.2025.065911 - 28 August 2025

Abstract Objectives: Checkpoint inhibitors have significantly improved outcomes in a number of malignancies. To determine the most effective course of treatment for head and neck squamous cell carcinoma (HNSCC), this systematic review evaluated the efficacy of several therapeutic approaches based on immune checkpoint inhibitors (ICIs). Methods: A comprehensive evaluation of the literature was conducted, looking at randomized controlled trials (RCTs) that were published in Embase, PubMed, and the Cochrane Central Register of Controlled Trials since database establishment. The risk of bias of the enrolled studies was analyzed using The Review Manager (RevMan) 5.4. Using network meta-analyses… More >

Jiahao Xue^1,#, Jingchang Zhang^2,#, Gang Chen³, Liucui Chen^4,*, Xinjun Lu^1,*

Oncology Research, Vol.33, No.9, pp. 2309-2329, 2025, DOI:10.32604/or.2025.063719 - 28 August 2025

Abstract Hepatocellular carcinoma (HCC) is a highly aggressive malignancy, largely driven by an immunosuppressive tumor microenvironment (TME) that facilitates tumor growth, immune escape, and resistance to therapy. Although immunotherapy—particularly immune checkpoint inhibitors (ICIs)—has transformed the therapeutic landscape by restoring T cell-mediated anti-tumor responses, their clinical benefit as monotherapy remains suboptimal. This limitation is primarily attributed to immunosuppressive components within the TME, including tumor-associated macrophages, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs). To address these challenges, combination strategies have been explored, such as dual checkpoint blockade targeting programmed cell death protein 1 (PD-1), programmed death-ligand More >

Filomena Emanuela Laddaga¹, Pamela Pinto², Bruna Daraia², Antonio D’amato^3,4, Stella D’oronzo^3,5, Stefano Martinotti^3,6,*, Francesco Gaudio^2,3,*

BIOCELL, Vol.49, No.7, pp. 1185-1206, 2025, DOI:10.32604/biocell.2025.063572 - 25 July 2025

Abstract Checkpoint inhibitors, particularly programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, have significantly advanced the treatment of Hodgkin lymphoma (HL), especially in relapsed or refractory cases. However, challenges such as resistance, immune-related adverse events (irAEs), and the need for effective patient selection remain. This review aims to explore the mechanisms of resistance to checkpoint inhibitors, including alterations in the tumor microenvironment, loss of antigen presentation, and T-cell exhaustion. Overcoming resistance may involve combination therapies, such as pairing PD-1 inhibitors with other immune checkpoint inhibitors or targeted therapies like Brentuximab vedotin. Additionally, next-generation inhibitors targeting molecules like More >